← Back to Search

Patients with history of COVID-19 infection and still experiencing symptoms (Long-COVID) for COVID Syndrome

Phase < 1
Recruiting
Led By Licia Luna, M.D., Ph.D.
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and up to 2 days follow-up after scan
Awards & highlights

Study Summary

This trial aims to test the safety of using a specific radiotracer called [11C]CPPC in PET imaging for people who have had COVID-19. The researchers want to see if this

Who is the study for?
This trial is for individuals who have had COVID-19. It's open to those with lingering symptoms (Long-COVID) and those without current symptoms. Participants must be suitable for PET scans using the [11C]CPPC radiotracer, but specific health requirements are not listed.Check my eligibility
What is being tested?
[11C]CPPC Injection is being tested in this study. The researchers want to see if it's safe and whether it shows differences in PET scan images between Long-COVID patients and recovered individuals without symptoms.See study design
What are the potential side effects?
The side effects of the [11C]CPPC injection aren't detailed here, but as a radiotracer used in PET imaging, potential risks may include allergic reactions or side effects from the substance itself.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and up to 2 days follow-up after scan
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and up to 2 days follow-up after scan for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of use of [11C]CPPC in patients with Long-COVID and healthy participants with history of COVID-19 infection as assessed by a change in complete blood count (CBC) test.
Safety of use of [11C]CPPC in patients with Long-COVID and healthy participants with history of COVID-19 infection as assessed by a change in complete metabolic panel (CMP) test.
To assess the safety and tolerability of one dose level of [11C]CPPC when administered intravenously.
Secondary outcome measures
Biodistribution of [11C]CPPC by PET imaging
Cognitive function as assessed by the NIH Toolbox Cognition Battery (NIHTB-CB)
Dementia as assessed by the Clinical Dementia Rating (CDR) scale
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Patients with history of COVID-19 infection and still experiencing symptoms (Long-COVID)Experimental Treatment1 Intervention
Participants with a diagnosis of Long- COVID will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
Group II: Healthy Participants with history of COVID-19 infection but not experiencing any symptoms.Experimental Treatment1 Intervention
Healthy participants (without any history of post-COVID symptoms) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,266 Previous Clinical Trials
14,837,491 Total Patients Enrolled
Radiological Society of North AmericaOTHER
25 Previous Clinical Trials
1,813 Total Patients Enrolled
Licia Luna, M.D., Ph.D.Principal InvestigatorJohns Hopkins University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment for participants in this study currently ongoing?

"According to the information available on clinicaltrials.gov, this specific clinical trial is not currently accepting patients. The trial was initially posted on February 1st, 2024 and last updated on January 23rd, 2024. However, it's worth noting that there are presently 133 other ongoing studies actively seeking participants at this time."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Long COVID-19 [11C]CPPC Study
2024. "Long COVID-19 [11C]CPPC Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06223971.
All > Survivor Corps
~3 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top